CD8A and neoplasm: Consistent with this duality, eliglustat treatment in tumor-bearing mice led to (1) Reduced tumor ganglioside levels and increased exposure of the major histocompatibility complex and tumor antigen peptides (2) Enhanced CD8+ T cell infiltration and (3) Synergistic tumor control when combined with anti–PD-1.